On February 29, 2024 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported recent accomplishments and provided a business outlook (Press release, AIM ImmunoTech, FEB 29, 2024, View Source [SID1234640648]). AIM’s dsRNA product candidate, Ampligen (rintatolimod), is being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Recent Highlights
AMP-518 Clinical Study: Phase 2 study evaluating Ampligen as a potential therapeutic for people with the Post-COVID condition of fatigue
Completed treatment in study
Reported positive topline results offering preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions
Bolstered intellectual property estate with issuance of key U.S. patent for Ampligen in combination with an anti-PD-L1 antibody for the treatment of cancer
DURIPANC Clinical Study: Phase 1b/2 clinical trial combining AIM’s Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of pancreatic cancer
Opened for enrollment and enrolled first subject at Erasmus Medical Center ("Erasmus MC")
First subject dosed at Erasmus MC
"AIM’s emphasis throughout 2024 will be building upon our strong foundation of scientific success," said AIM Chief Executive Officer Thomas K. Equels. "Our drug Ampligen is being evaluated in multiple indications – including pancreatic cancer, ovarian cancer and Post-COVID conditions – and we believe that success in any one of these areas would mean both dramatic improvement in people’s lives and significant value for our stockholders."
Upcoming Expected Ampligen Milestones
Q1 2024
Advanced Recurrent Ovarian Cancer – Protocol-planned interim results
Q2 2024
Post-COVID Conditions (AMP-518) – Final dataset
2024
Locally Advanced Pancreatic Adenocarcinoma (AMP-270) – First subject dosed
Publications of data in scientific journals
Ongoing Business Development Update
As previously announced, the Company engaged Azenova, LLC ("Azenova"), a professional business development (BD) consulting firm, to support efforts to partner AIM’s pipeline programs with a particular focus on the Company’s lead asset, Ampligen, for the treatment of various malignant solid tumors. Discussions for potential partnership, licensing, and other transactional activities remain ongoing.
In addition to its ongoing clinical and business development activities, the Company will continue to engage with the industry and investment communities by actively participating in meetings, virtual events and key conferences over the course of the year. To stay up to date with the Company’s activities visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.